Eli Lilly And Co (NYSE:LLY) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 103,663,031 shares, an increase of 193.9% from the February 15th total of 35,274,912 shares. Based on an average trading volume of 22,593,431 shares, the days-to-cover ratio is presently 4.6 days. Approximately 11.3% of the company’s shares are sold short.

A number of brokerages have recently commented on LLY. Citigroup set a $124.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Tuesday, February 26th. JPMorgan Chase & Co. began coverage on shares of Eli Lilly And Co in a research report on Tuesday. They set an “overweight” rating and a $140.00 target price on the stock. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Zacks Investment Research lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, December 4th. Finally, UBS Group reduced their target price on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research report on Friday, February 8th. Eleven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $113.06.

Shares of LLY stock opened at $123.94 on Friday. The company has a market cap of $127.87 billion, a P/E ratio of 22.33, a price-to-earnings-growth ratio of 2.49 and a beta of 0.33. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.73. Eli Lilly And Co has a 52-week low of $74.51 and a 52-week high of $130.75.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). The business had revenue of $6.44 billion for the quarter, compared to analysts’ expectations of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.14 earnings per share. Sell-side analysts anticipate that Eli Lilly And Co will post 5.62 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 8th. Investors of record on Friday, February 15th were issued a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a yield of 2.08%. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date of this dividend was Thursday, February 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.

In other news, SVP Stephen F. Fry sold 14,847 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $123.16, for a total transaction of $1,828,556.52. Following the transaction, the senior vice president now directly owns 109,663 shares of the company’s stock, valued at $13,506,095.08. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 51,766 shares of the firm’s stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $117.74, for a total transaction of $6,094,928.84. Following the transaction, the insider now directly owns 117,963,538 shares in the company, valued at $13,889,026,964.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 833,190 shares of company stock worth $102,388,102. Corporate insiders own 0.11% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Captrust Financial Advisors boosted its stake in Eli Lilly And Co by 0.4% in the fourth quarter. Captrust Financial Advisors now owns 21,627 shares of the company’s stock valued at $2,503,000 after acquiring an additional 87 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its stake in Eli Lilly And Co by 1.6% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 5,543 shares of the company’s stock valued at $641,000 after acquiring an additional 87 shares in the last quarter. First Personal Financial Services boosted its stake in Eli Lilly And Co by 2.3% in the fourth quarter. First Personal Financial Services now owns 3,931 shares of the company’s stock valued at $455,000 after acquiring an additional 89 shares in the last quarter. Carroll Financial Associates Inc. boosted its stake in Eli Lilly And Co by 1.3% in the fourth quarter. Carroll Financial Associates Inc. now owns 7,029 shares of the company’s stock valued at $810,000 after acquiring an additional 91 shares in the last quarter. Finally, Bailard Inc. boosted its stake in Eli Lilly And Co by 3.6% in the fourth quarter. Bailard Inc. now owns 2,672 shares of the company’s stock valued at $309,000 after acquiring an additional 92 shares in the last quarter. 77.00% of the stock is currently owned by institutional investors.

WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2019/03/16/eli-lilly-and-co-lly-short-interest-update-2.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: No Load Funds

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.